573 related articles for article (PubMed ID: 19833260)
1. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
3. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.
Santos PC; Gagliardi AC; Miname MH; Chacra AP; Santos RD; Krieger JE; Pereira AC
Eur J Clin Pharmacol; 2012 Mar; 68(3):273-9. PubMed ID: 21928084
[TBL] [Abstract][Full Text] [Related]
4. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Hou Q; Li S; Li L; Li Y; Sun X; Tian H
Medicine (Baltimore); 2015 Sep; 94(37):e1268. PubMed ID: 26376374
[TBL] [Abstract][Full Text] [Related]
5. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
[TBL] [Abstract][Full Text] [Related]
6. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
7. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Romaine SP; Bailey KM; Hall AS; Balmforth AJ
Pharmacogenomics J; 2010 Feb; 10(1):1-11. PubMed ID: 19884908
[TBL] [Abstract][Full Text] [Related]
8. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
9. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
[TBL] [Abstract][Full Text] [Related]
10. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
[TBL] [Abstract][Full Text] [Related]
11. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
12. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.
Carr DF; O'Meara H; Jorgensen AL; Campbell J; Hobbs M; McCann G; van Staa T; Pirmohamed M
Clin Pharmacol Ther; 2013 Dec; 94(6):695-701. PubMed ID: 23942138
[TBL] [Abstract][Full Text] [Related]
13. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
Ferrari M; Guasti L; Maresca A; Mirabile M; Contini S; Grandi AM; Marino F; Cosentino M
Eur J Clin Pharmacol; 2014 May; 70(5):539-47. PubMed ID: 24595600
[TBL] [Abstract][Full Text] [Related]
14. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.
Hermann M; Bogsrud MP; Molden E; Asberg A; Mohebi BU; Ose L; Retterstøl K
Clin Pharmacol Ther; 2006 Jun; 79(6):532-9. PubMed ID: 16765141
[TBL] [Abstract][Full Text] [Related]
15. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
[TBL] [Abstract][Full Text] [Related]
16. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
Canestaro WJ; Austin MA; Thummel KE
Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
[TBL] [Abstract][Full Text] [Related]
17. [Genetic marker of statin-induced rhabdomyolysis].
Chiba K; Morimoto K
Yakugaku Zasshi; 2011 Feb; 131(2):247-53. PubMed ID: 21297370
[TBL] [Abstract][Full Text] [Related]
18. Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy.
Alghalyini B; El Shamieh S; Salami A; Visvikis Siest S; Fakhoury HM; Fakhoury R
Drug Metab Pers Ther; 2018 Mar; 33(1):41-47. PubMed ID: 29420305
[TBL] [Abstract][Full Text] [Related]
19. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
Kameyama Y; Yamashita K; Kobayashi K; Hosokawa M; Chiba K
Pharmacogenet Genomics; 2005 Jul; 15(7):513-22. PubMed ID: 15970799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]